251
|
Triolo M, Annema W, de Boer JF, Tietge UJF, Dullaart RPF. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest 2014; 44:240-8. [PMID: 24325778 DOI: 10.1111/eci.12226] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2013] [Accepted: 12/07/2013] [Indexed: 12/17/2022]
Abstract
BACKGROUND The importance of functional properties of high-density lipoproteins (HDL) for atheroprotection is increasingly recognized. We determined the impact of lipid-lowering therapy on 3 key HDL functionalities in Type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS A placebo-controlled, randomized cross-over study (three 8-week treatment periods with simvastatin (40 mg daily), bezafibrate (400 mg daily), alone and in combination) was carried out in 14 men with T2DM. Cholesterol efflux was determined using human THP-1 monocyte-derived macrophages, HDL antioxidative capacity was measured as inhibition of low-density lipoprotein oxidation in vitro, and HDL anti-inflammatory capacity was assessed as suppression of thrombin-induced monocyte chemotactic protein 1 expression in human umbilical vein endothelial cells. Pre-β-HDL was assayed using crossed immunoelectrophoresis. RESULTS While cholesterol efflux increased in response to simvastatin, bezafibrate and combination treatment (+12 to +23%; anova, P = 0.001), HDL antioxidative capacity (P = 0.23) and HDL anti-inflammatory capacity (P = 0.15) did not change significantly. Averaged changes in cellular cholesterol efflux during active treatment were correlated positively with changes in HDL cholesterol, apoA-I and pre-β-HDL (P < 0.05 to P < 0.001). There were no inter-relationships between changes in the three HDL functionalities during treatment (P > 0.10). Changes in HDL antioxidative capacity and anti-inflammatory capacity were also unrelated to changes in HDL cholesterol and apoA-I, while changes in HDL antioxidative capacity were related inversely to pre-β-HDL (P < 0.05). CONCLUSION Simvastatin and bezafibrate increase cholesterol efflux, parallel to HDL cholesterol and apoA-I responses. The antioxidative and anti-inflammatory properties of HDL are not to an important extent affected by these therapeutic interventions.
Collapse
Affiliation(s)
- Michela Triolo
- Department of Endocrinology, Center for Liver, Digestive and Metabolic Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Pediatrics, Center for Liver, Digestive and Metabolic Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | | | | | | | | |
Collapse
|
252
|
McLure KG, Gesner EM, Tsujikawa L, Kharenko OA, Attwell S, Campeau E, Wasiak S, Stein A, White A, Fontano E, Suto RK, Wong NCW, Wagner GS, Hansen HC, Young PR. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One 2013; 8:e83190. [PMID: 24391744 PMCID: PMC3877016 DOI: 10.1371/journal.pone.0083190] [Citation(s) in RCA: 148] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2013] [Accepted: 11/09/2013] [Indexed: 12/19/2022] Open
Abstract
Increased synthesis of Apolipoprotein A-I (ApoA-I) and HDL is believed to provide a new approach to treating atherosclerosis through the stimulation of reverse cholesterol transport. RVX-208 increases the production of ApoA-I in hepatocytes in vitro, and in vivo in monkeys and humans, which results in increased HDL-C, but the molecular target was not previously reported. Using binding assays and X-ray crystallography, we now show that RVX-208 selectively binds to bromodomains of the BET (Bromodomain and Extra Terminal) family, competing for a site bound by the endogenous ligand, acetylated lysine, and that this accounts for its pharmacological activity. siRNA experiments further suggest that induction of ApoA-I mRNA is mediated by BET family member BRD4. These data indicate that RVX-208 increases ApoA-I production through an epigenetic mechanism and suggests that BET inhibition may be a promising new approach to the treatment of atherosclerosis.
Collapse
Affiliation(s)
- Kevin G McLure
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| | - Emily M Gesner
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| | - Laura Tsujikawa
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| | - Olesya A Kharenko
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| | - Sarah Attwell
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| | - Eric Campeau
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| | - Sylwia Wasiak
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| | - Adam Stein
- Xtal BioStructures Inc., Natick, Maryland, United States of America
| | - Andre White
- Xtal BioStructures Inc., Natick, Maryland, United States of America
| | - Eric Fontano
- Xtal BioStructures Inc., Natick, Maryland, United States of America
| | - Robert K Suto
- Xtal BioStructures Inc., Natick, Maryland, United States of America
| | - Norman C W Wong
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| | - Gregory S Wagner
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| | - Henrik C Hansen
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| | - Peter R Young
- Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America
| |
Collapse
|
253
|
Pérez-Méndez Ó, Pacheco HG, Martínez-Sánchez C, Franco M. HDL-cholesterol in coronary artery disease risk: function or structure? Clin Chim Acta 2013; 429:111-22. [PMID: 24333390 DOI: 10.1016/j.cca.2013.12.001] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Revised: 11/29/2013] [Accepted: 12/01/2013] [Indexed: 12/29/2022]
Abstract
High-density lipoproteins (HDL) are inversely related with coronary artery disease (CAD) and HDL-cholesterol is the only standardized and reproducible parameter available to estimate plasma concentration of these lipoproteins. However, pharmacological interventions intended to increase HDL-cholesterol have not been consistently associated to an effective CAD risk reduction. Among patients with a myocardial infarction, 43 and 44% of men and women, respectively, had normal plasma levels of HDL-cholesterol, whereas genetic studies have failed to show a causal association between HDL-cholesterol and CAD risk. Instead, HDL functionality seems to be the target to be evaluated, but the existing methods are still poorly reproducible and far to be adapted to the clinical laboratory. HDL subclasses rise as a potential alternative for the evaluation of CAD risk; HDL subclasses are a surrogate of intravascular metabolism of these lipoproteins and probably of their functionality. Low levels of large HDL and increased proportions of small particles are the most remarkable features associated to an increased risk of type 2 diabetes mellitus (T2DM) or CAD. However, inflammation and other environmental factors are related with abnormal HDL structure, and, as a consequence, more prospective studies are needed to better support the clinical usefulness of HDL subclasses. New insights from proteome and lipidome profiles of HDL will provide potential HDL-related biomarkers in the coming years.
Collapse
Affiliation(s)
- Óscar Pérez-Méndez
- Department of Molecular Biology, National Institute of Cardiology "Ignacio Chávez", Mexico, DF, Mexico.
| | - Héctor González Pacheco
- Department of Emergency, National Institute of Cardiology "Ignacio Chávez", Mexico, DF, Mexico
| | - Carlos Martínez-Sánchez
- Department of Emergency, National Institute of Cardiology "Ignacio Chávez", Mexico, DF, Mexico
| | - Martha Franco
- Department of Molecular Biology, National Institute of Cardiology "Ignacio Chávez", Mexico, DF, Mexico
| |
Collapse
|
254
|
Weibel GL, Drazul-Schrader D, Shivers DK, Wade AN, Rothblat GH, Reilly MP, de la Llera-Moya M. Importance of evaluating cell cholesterol influx with efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2013; 34:17-25. [PMID: 24202308 DOI: 10.1161/atvbaha.113.302437] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
OBJECTIVE Cholesterol efflux relates to cardiovascular disease but cannot predict cellular cholesterol mass changes. We asked whether influx and net flux assays provide additional insights. APPROACH AND RESULTS Adapt a bidirectional flux assay to cells where efflux has clinical correlates and examine the association of influx, efflux, and net flux to serum triglycerides (TGs). Apolipoprotein B-depleted (high-density lipoprotein-fraction) serum from individuals with unfavorable lipids (median [interquartile range]; high-density lipoprotein-cholesterol=39 [32-42], low-density lipoprotein-cholesterol=109 [97-137], TGs=258 [184-335] mg/dL; n=13) promoted greater ATP-binding cassette transporter A1-mediated [1,2-(3H)] cholesterol efflux (3.8±0.3%/4 hour versus 1.2±0.4%/4 hour; P<0.0001) from cyclic 3',5'-amp(CTP-amp)-treated J774 macrophages than from individuals with favorable lipids (high-density lipoprotein-cholesterol=72 [58-88], low-density lipoprotein-cholesterol=111 [97-131], TGs=65 [56-69] mg/dL; n=10). Thus, high TGs associated with more ATP-binding cassette transporter A1 acceptors. Efflux of cholesterol mass (μg free cholesterol/mg cell protein per 8 hour) to serum was also higher (7.06±0.33 versus 5.83±0.48; P=0.04). However, whole sera from individuals with unfavorable lipids promoted more influx (5.14±0.65 versus 2.48±0.85; P=0.02) and lower net release of cholesterol mass (1.93±0.46 versus 3.36±0.47; P=0.04). The pattern differed when mass flux was measured using apolipoprotein B-depleted serum rather than serum. Although individuals with favorable lipids tended to have greater influx than those with unfavorable lipids, efflux to apolipoprotein B-depleted serum was markedly higher (6.81±0.04 versus 2.62±0.14; P<0.0001), resulting in an efflux:influx ratio of ≈3-fold. Thus both serum and apolipoprotein B-depleted serum from individuals with favorable lipids promoted greater net cholesterol mass release despite increased ATP-binding cassette transporter A1-mediated efflux in samples of individuals with high TGs/unfavorable lipids. CONCLUSIONS When considering the efficiency of serum specimens to modulate cell cholesterol content, both influx and efflux need to be measured.
Collapse
Affiliation(s)
- Ginny L Weibel
- From the Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, PA (G.L.W., D.D.-S., D.K.S., G.H.R., M.d.l.L.-M.); Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia (M.P.R.); and School of Public Health and School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (A.N.W.)
| | | | | | | | | | | | | |
Collapse
|
255
|
Vasudevan M, Tchoua U, Gillard BK, Jones PH, Ballantyne CM, Pownall HJ. Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. J Clin Lipidol 2013; 7:661-70. [PMID: 24314365 PMCID: PMC4108339 DOI: 10.1016/j.jacl.2013.05.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2013] [Revised: 05/15/2013] [Accepted: 05/20/2013] [Indexed: 11/15/2022]
Abstract
BACKGROUND Obesity-linked metabolic syndrome (MetS) is associated with a dyslipidemic profile that includes hypertriglyceridemia and low plasma high-density lipoprotein (HDL) cholesterol. HDL initiates reverse cholesterol transport via macrophage cholesterol efflux (MCE). Some hypothesize that dyslipidemic patients have impaired reverse cholesterol transport. MCE to patient plasma, a metric of HDL function, inversely correlates with atherosclerotic burden. Paradoxically, MCE to plasma of hypertriglyceridemic subjects is higher than that to normolipidemic (NL) plasma. OBJECTIVE Although weight loss reduces dyslipidemia, its effect on MCE to the plasma of obese patients with MetS is unknown. Thus, we tested the hypothesis that reducing dyslipidemia with weight loss reduces the MCE capacity of MetS plasma to that of NL plasma. METHODS Cholesterol efflux (MCE) from THP-1 macrophages to plasma from NL controls and to obese patients with MetS before and after weight loss was measured. RESULTS MCE to plasma of obese patients with MetS was higher than that of control plasma (P = .006). Weight loss in patients with MetS (mean, -9.77 kg) reduced dyslipidemia, insulin resistance, and systolic blood pressure. HDL cholesterol was unchanged, and apolipoprotein A-I decreased with weight loss. Weight loss in patients with MetS normalized MCE (P < .001) to that of NL subjects. MCE correlated with apolipoprotein B levels (r² = 0.13-0.38). Chromatography showed that macrophage cholesterol initially associates with HDL but accumulates in apolipoprotein B-containing lipoproteins at later times. CONCLUSIONS Although the initial acceptor of MCE is HDL, the elevated apolipoprotein B lipoproteins are a cholesterol sink that increases MCE in patients with MetS. Weight loss results in decreased apolipoprotein B lipoproteins and decreased MCE to plasma of patients with MetS.
Collapse
Affiliation(s)
- Madhuri Vasudevan
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
| | - Urbain Tchoua
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
| | - Baiba K. Gillard
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
| | - Peter H. Jones
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
- The Methodist Hospital DeBakey Heart and Vascular Center, 6565 Fannin St., Houston TX 77030
| | - Christie M. Ballantyne
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
- The Methodist Hospital DeBakey Heart and Vascular Center, 6565 Fannin St., Houston TX 77030
| | - Henry J. Pownall
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
| |
Collapse
|
256
|
Evidence for a role of CETP in HDL remodeling and cholesterol efflux: Role of cysteine 13 of CETP. Biochim Biophys Acta Mol Cell Biol Lipids 2013; 1831:1644-50. [DOI: 10.1016/j.bbalip.2013.07.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Revised: 07/09/2013] [Accepted: 07/12/2013] [Indexed: 01/29/2023]
|
257
|
Leman LJ, Maryanoff BE, Ghadiri MR. Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J Med Chem 2013; 57:2169-96. [PMID: 24168751 DOI: 10.1021/jm4005847] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Certain amphipathic α-helical peptides can functionally mimic many of the properties of full-length apolipoproteins, thereby offering an approach to modulate high-density lipoprotein (HDL) for combating atherosclerosis. In this Perspective, we summarize the key findings and advances over the past 25 years in the development of peptides that mimic apolipoproteins, especially apolipoprotein A-I (apoA-I). This assemblage of information provides a reasonably clear picture of the state of the art in the apolipoprotein mimetic field, an appreciation of the potential for such agents in pharmacotherapy, and a sense of the opportunities for optimizing the functional properties of HDL.
Collapse
Affiliation(s)
- Luke J Leman
- Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | | | | |
Collapse
|
258
|
Abstract
At least 468 individual genes have been manipulated by molecular methods to study their effects on the initiation, promotion, and progression of atherosclerosis. Most clinicians and many investigators, even in related disciplines, find many of these genes and the related pathways entirely foreign. Medical schools generally do not attempt to incorporate the relevant molecular biology into their curriculum. A number of key signaling pathways are highly relevant to atherogenesis and are presented to provide a context for the gene manipulations summarized herein. The pathways include the following: the insulin receptor (and other receptor tyrosine kinases); Ras and MAPK activation; TNF-α and related family members leading to activation of NF-κB; effects of reactive oxygen species (ROS) on signaling; endothelial adaptations to flow including G protein-coupled receptor (GPCR) and integrin-related signaling; activation of endothelial and other cells by modified lipoproteins; purinergic signaling; control of leukocyte adhesion to endothelium, migration, and further activation; foam cell formation; and macrophage and vascular smooth muscle cell signaling related to proliferation, efferocytosis, and apoptosis. This review is intended primarily as an introduction to these key signaling pathways. They have become the focus of modern atherosclerosis research and will undoubtedly provide a rich resource for future innovation toward intervention and prevention of the number one cause of death in the modern world.
Collapse
Affiliation(s)
- Paul N Hopkins
- Cardiovascular Genetics, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
| |
Collapse
|
259
|
Sengupta B, Narasimhulu CA, Parthasarathy S. Novel technique for generating macrophage foam cells for in vitro reverse cholesterol transport studies. J Lipid Res 2013; 54:3358-72. [PMID: 24115226 PMCID: PMC3826683 DOI: 10.1194/jlr.m041327] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Generation of foam cells, an essential step for reverse cholesterol transport studies, uses the technique of receptor-dependent macrophage loading with radiolabeled acetylated LDL. In this study, we used the ability of a biologically relevant detergent molecule, lysophosphatidylcholine (lyso-PtdCho), to form mixed micelles with cholesterol or cholesteryl ester (CE) to generate macrophage foam cells. Fluorescent or radiolabeled cholesterol/lyso-PtdCho mixed micelles were prepared and incubated with RAW 264.7 or mouse peritoneal macrophages. Results showed that such micelles were quite stable at 4°C and retained the solubilized cholesterol during one month of storage. Macrophages incubated with cholesterol or CE (unlabeled, fluorescently labeled, or radiolabeled)/lyso-PtdCho mixed micelles accumulated CE as documented by microscopy, lipid staining, labeled oleate incorporation, and by TLC. Such foam cells unloaded cholesterol when incubated with HDL but not with oxidized HDL. We propose that stable cholesterol or CE/lyso-PtdCho micelles would offer advantages over existing methods.
Collapse
Affiliation(s)
- Bhaswati Sengupta
- Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827
| | | | | |
Collapse
|
260
|
Rosenson RS, Brewer HB, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of High-Density Lipoprotein Function Into Clinical Practice. Circulation 2013; 128:1256-67. [DOI: 10.1161/circulationaha.113.000962] [Citation(s) in RCA: 164] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Robert S. Rosenson
- From the Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC (H.B.B.); Atherosclerosis Research Unit, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA (B.A.); Centre for Vascular Research at the University of New South Wales, Sydney, Australia (P.B.); Dyslipidemia, Atherosclerosis and Inflammation Research Unit 939, National
| | - H. Bryan Brewer
- From the Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC (H.B.B.); Atherosclerosis Research Unit, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA (B.A.); Centre for Vascular Research at the University of New South Wales, Sydney, Australia (P.B.); Dyslipidemia, Atherosclerosis and Inflammation Research Unit 939, National
| | - Benjamin Ansell
- From the Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC (H.B.B.); Atherosclerosis Research Unit, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA (B.A.); Centre for Vascular Research at the University of New South Wales, Sydney, Australia (P.B.); Dyslipidemia, Atherosclerosis and Inflammation Research Unit 939, National
| | - Philip Barter
- From the Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC (H.B.B.); Atherosclerosis Research Unit, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA (B.A.); Centre for Vascular Research at the University of New South Wales, Sydney, Australia (P.B.); Dyslipidemia, Atherosclerosis and Inflammation Research Unit 939, National
| | - M. John Chapman
- From the Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC (H.B.B.); Atherosclerosis Research Unit, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA (B.A.); Centre for Vascular Research at the University of New South Wales, Sydney, Australia (P.B.); Dyslipidemia, Atherosclerosis and Inflammation Research Unit 939, National
| | - Jay W. Heinecke
- From the Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC (H.B.B.); Atherosclerosis Research Unit, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA (B.A.); Centre for Vascular Research at the University of New South Wales, Sydney, Australia (P.B.); Dyslipidemia, Atherosclerosis and Inflammation Research Unit 939, National
| | - Anatol Kontush
- From the Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC (H.B.B.); Atherosclerosis Research Unit, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA (B.A.); Centre for Vascular Research at the University of New South Wales, Sydney, Australia (P.B.); Dyslipidemia, Atherosclerosis and Inflammation Research Unit 939, National
| | - Alan R. Tall
- From the Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC (H.B.B.); Atherosclerosis Research Unit, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA (B.A.); Centre for Vascular Research at the University of New South Wales, Sydney, Australia (P.B.); Dyslipidemia, Atherosclerosis and Inflammation Research Unit 939, National
| | - Nancy R. Webb
- From the Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.); Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC (H.B.B.); Atherosclerosis Research Unit, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA (B.A.); Centre for Vascular Research at the University of New South Wales, Sydney, Australia (P.B.); Dyslipidemia, Atherosclerosis and Inflammation Research Unit 939, National
| |
Collapse
|
261
|
Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. High-density lipoproteins: A consensus statement from the National Lipid Association. J Clin Lipidol 2013; 7:484-525. [DOI: 10.1016/j.jacl.2013.08.001] [Citation(s) in RCA: 240] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Accepted: 08/03/2013] [Indexed: 12/21/2022]
|
262
|
Medina-Bravo P, Medina-Urrutia A, Juárez-Rojas JG, Cardoso-Saldaña G, Jorge-Galarza E, Posadas-Sánchez R, Coyote-Estrada N, Nishimura-Meguro E, Posadas-Romero C. Glycemic control and high-density lipoprotein characteristics in adolescents with type 1 diabetes. Pediatr Diabetes 2013; 14:399-406. [PMID: 23057424 DOI: 10.1111/j.1399-5448.2012.00924.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2012] [Revised: 07/03/2012] [Accepted: 08/02/2012] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Recent evidence suggests that high-density lipoprotein (HDL) physicochemical characteristics and functional capacity may be more important that HDL-C levels in predicting coronary heart disease. There is little data regarding HDL subclasses distribution in youth with type 1 diabetes. OBJECTIVE To assess the relationships between glycemic control and HDL subclasses distribution, composition, and function in adolescents with type 1 diabetes. METHODS This cross-sectional study included 52 adolescents with type 1 diabetes aged 12-16 years and 43 age-matched non-diabetic controls. Patients were divided into two groups: one in fair control [hemoglobin A1c (HbA1c) < 9.6%] and the second group with poor glycemic control (HbA1c ≥ 9.6%). In all participants, we determined HDL subclasses distribution, composition, and the ability of plasma and of isolated HDL to promote cellular cholesterol efflux. Levels of soluble adhesion molecules were also measured. RESULTS Although both groups of patients and the control group had similar HDL-C levels, linear regression analyses showed that compared with non-diabetic subjects, the poor control group had a lower proportion of HDL2b subclass (p = 0.029), triglyceride enriched (p = 0.045), and cholesteryl ester depleted (p = 0.028) HDL particles. Despite these HDL changes, cholesterol efflux was comparable among the three groups. The poor control group also had significantly higher intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 plasma concentrations. CONCLUSIONS In adolescents with type 1 diabetes, poor glycemic control is associated with abnormalities in HDL subclasses distribution and HDL lipid composition, however, in spite of these HDL changes, the ability of HDL to promote cholesterol efflux remains comparable to that of healthy subjects.
Collapse
Affiliation(s)
- Patricia Medina-Bravo
- Department of Endocrinology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico
| | | | | | | | | | | | | | | | | |
Collapse
|
263
|
Dávalos A, Fernández-Hernando C. From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport. Pharmacol Res 2013; 75:60-72. [PMID: 23435093 PMCID: PMC3825518 DOI: 10.1016/j.phrs.2013.02.005] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Accepted: 02/11/2013] [Indexed: 02/09/2023]
Abstract
There has been strong evolutionary pressure to ensure that an animal cell maintains levels of cholesterol within tight limits for normal function. Imbalances in cellular cholesterol levels are a major player in the development of different pathologies associated to dietary excess. Although epidemiological studies indicate that elevated levels of high-density lipoprotein (HDL)-cholesterol reduce the risk of cardiovascular disease, recent genetic evidence and pharmacological therapies to raise HDL levels do not support their beneficial effects. Cholesterol efflux as the first and probably the most important step in reverse cholesterol transport is an important biological process relevant to HDL function. Small non-coding RNAs (microRNAs), post-transcriptional control different aspects of cellular cholesterol homeostasis including cholesterol efflux. miRNA families miR-33, miR-758, miR-10b, miR-26 and miR-106b directly modulates cholesterol efflux by targeting the ATP-binding cassette transporter A1 (ABCA1). Pre-clinical studies with anti-miR therapies to inhibit some of these miRNAs have increased cellular cholesterol efflux, reverse cholesterol transport and reduce pathologies associated to dyslipidemia. Although miRNAs as therapy have benefits from existing antisense technology, different obstacles need to be solved before we incorporate such research into clinical care. Here we focus on the clinical potential of miRNAs as therapeutic target to increase cholesterol efflux and reverse cholesterol transport as a new alternative to ameliorate cholesterol-related pathologies.
Collapse
|
264
|
Borja MS, Zhao L, Hammerson B, Tang C, Yang R, Carson N, Fernando G, Liu X, Budamagunta MS, Genest J, Shearer GC, Duclos F, Oda MN. HDL-apoA-I exchange: rapid detection and association with atherosclerosis. PLoS One 2013; 8:e71541. [PMID: 24015188 PMCID: PMC3756009 DOI: 10.1371/journal.pone.0071541] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2013] [Accepted: 06/28/2013] [Indexed: 01/23/2023] Open
Abstract
High density lipoprotein (HDL) cholesterol levels are associated with decreased risk of cardiovascular disease, but not all HDL are functionally equivalent. A primary determinant of HDL functional status is the conformational adaptability of its main protein component, apoA-I, an exchangeable apolipoprotein. Chemical modification of apoA-I, as may occur under conditions of inflammation or diabetes, can severely impair HDL function and is associated with the presence of cardiovascular disease. Chemical modification of apoA-I also impairs its ability to exchange on and off HDL, a critical process in reverse cholesterol transport. In this study, we developed a method using electron paramagnetic resonance spectroscopy (EPR) to quantify HDL-apoA-I exchange. Using this approach, we measured the degree of HDL-apoA-I exchange for HDL isolated from rabbits fed a high fat, high cholesterol diet, as well as human subjects with acute coronary syndrome and metabolic syndrome. We observed that HDL-apoA-I exchange was markedly reduced when atherosclerosis was present, or when the subject carries at least one risk factor of cardiovascular disease. These results show that HDL-apoA-I exchange is a clinically relevant measure of HDL function pertinent to cardiovascular disease.
Collapse
Affiliation(s)
- Mark S. Borja
- Children's Hospital Oakland Research Institute, Oakland, California, United States of America
| | - Lei Zhao
- Cardiovascular Drug Discovery, Bristol-Myers Squibb Company, Pennington, New Jersey, United States of America
| | - Bradley Hammerson
- Accent Assays, Inc., Sacramento, California, United States of America
| | - Chongren Tang
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Richard Yang
- Cardiovascular Drug Discovery, Bristol-Myers Squibb Company, Pennington, New Jersey, United States of America
| | - Nancy Carson
- Cardiovascular Drug Discovery, Bristol-Myers Squibb Company, Pennington, New Jersey, United States of America
| | - Gayani Fernando
- Cardiovascular Drug Discovery, Bristol-Myers Squibb Company, Pennington, New Jersey, United States of America
| | - Xiaoqin Liu
- Cardiovascular Drug Discovery, Bristol-Myers Squibb Company, Pennington, New Jersey, United States of America
| | - Madhu S. Budamagunta
- Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, California, United States of America
| | - Jacques Genest
- Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
| | - Gregory C. Shearer
- Cardiovascular Health Research Center, Sanford Research/USD, Sioux Falls, South Dakota, United States of America
- Department of Internal Medicine and Department of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota, United States of America
| | - Franck Duclos
- Cardiovascular Drug Discovery, Bristol-Myers Squibb Company, Pennington, New Jersey, United States of America
| | - Michael N. Oda
- Children's Hospital Oakland Research Institute, Oakland, California, United States of America
- * E-mail:
| |
Collapse
|
265
|
Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Invest Dermatol 2013; 134:635-642. [PMID: 23985995 DOI: 10.1038/jid.2013.359] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2013] [Revised: 07/24/2013] [Accepted: 08/04/2013] [Indexed: 12/21/2022]
Abstract
Psoriasis is a chronic inflammatory disorder associated with increased cardiovascular mortality. Psoriasis affects high-density lipoprotein (HDL) composition, generating dysfunctional HDL particles. However, data regarding the impact of anti-psoriatic therapy on HDL composition and function are not available. HDL was isolated from 15 psoriatic patients at baseline and after effective topical and/or systemic anti-psoriatic therapy and from 15 age- and sex-matched healthy controls. HDL from psoriatic patients showed a significantly impaired capability to mobilize cholesterol from macrophages (6.4 vs. 8.0% [(3)H]cholesterol efflux, P<0.001), low paraoxonase (217 vs. 350 μM(-1) minute(-1) mg(-1) protein, P=0.011) and increased Lp-PLA2 activities (19.9 vs. 12.1 nM(-1) minute(-1) mg(-1) protein, P=0.028). Of particular interest, the anti-psoriatic therapy significantly improved serum lecithin-cholesterol acyltransferase activity and decreased total serum lipolytic activity but did not affect serum levels of HDL-cholesterol. Most importantly, these changes were associated with a significantly improved HDL-cholesterol efflux capability. Our results provide evidence that effective anti-psoriatic therapy recovers HDL composition and function, independent of serum HDL-cholesterol levels, and support to the emerging concept that HDL function may be a better marker of cardiovascular risk than HDL-cholesterol levels.
Collapse
|
266
|
Zhao Y, Imura T, Leman LJ, Curtiss LK, Maryanoff BE, Ghadiri MR. Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs. J Am Chem Soc 2013; 135:13414-24. [PMID: 23978057 DOI: 10.1021/ja404714a] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
We describe an approach for engineering peptide-lipid nanoparticles that function similarly to high-density lipoprotein (HDL). Branched, multivalent constructs, bearing multiple 23- or 16-amino-acid peptides, were designed, synthesized, and combined with phospholipids to produce nanometer-scale discoidal HDL-like particles. A variety of biophysical techniques were employed to characterize the constructs, including size exclusion chromatography, analytical ultracentrifuge sedimentation, circular dichroism, transmission electron microscopy, and fluorescence spectroscopy. The nanoparticles functioned in vitro (human and mouse plasma) and in vivo (mice) to rapidly remodel large native HDLs into small lipid-poor HDL particles, which are key acceptors of cholesterol in reverse cholesterol transport. Fluorescent labeling studies showed that the constituents of the nanoparticles readily distributed into native HDLs, such that the peptide constructs coexisted with apolipoprotein A-I (apoA-I), the main structural protein in HDLs. Importantly, nanolipid particles containing multivalent peptides promoted efficient cellular cholesterol efflux and were functionally superior to those derived from monomeric apoA-I mimetic peptides. The multivalent peptide-lipid nanoparticles were also remarkably stable toward enzymatic digestion in vitro and displayed long half-lives and desirable pharmacokinetic profiles in mice, providing a real practical advantage over previously studied linear or tandem helical peptides. Encouragingly, a two-week exploratory efficacy study in a widely used animal model for atherosclerosis research (LDLr-null mice) using nanoparticles constructed from a trimeric peptide demonstrated an exceptional 50% reduction in the plasma total cholesterol levels compared to the control group. Altogether, the studies reported here point to an attractive avenue for designing synthetic, HDL-like nanoparticles, with potential for treating atherosclerosis.
Collapse
Affiliation(s)
- Yannan Zhao
- Department of Chemistry, ‡Department of Immunology and Microbial Science, and §The Skaggs Institute for Chemical Biology, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | | | | | | | | | | |
Collapse
|
267
|
Kempen HJ, Gomaraschi M, Bellibas SE, Plassmann S, Zerler B, Collins HL, Adelman SJ, Calabresi L, Wijngaard PLJ. Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys. J Lipid Res 2013; 54:2341-53. [PMID: 23828780 DOI: 10.1194/jlr.m033779] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
MDCO-216, a complex of dimeric recombinant apoA-IMilano (apoA-IM) and palmitoyl-oleoyl-phosphatidylcholine (POPC), was administered to cynomolgus monkeys at 30, 100, and 300 mg/kg every other day for a total of 21 infusions, and effects on lipids, (apo)lipoproteins, and ex-vivo cholesterol efflux capacity were monitored. After 7 or 20 infusions, free cholesterol (FC) and phospholipids (PL) were strongly increased, and HDL-cholesterol (HDL-C), apoA-I, and apoA-II were strongly decreased. We then measured short-term effects on apoA-IM, lipids, and (apo)lipoproteins after the first or the last infusion. After the first infusion, PL and FC went up in the HDL region and also in the LDL and VLDL regions. ApoE shifted from HDL to LDL and VLDL regions, while ApoA-IM remained located in the HDL region. On day 41, ApoE levels were 8-fold higher than on day 1, and FC, PL, and apoE resided mostly in LDL and VLDL regions. Drug infusion quickly decreased the endogenous cholesterol esterification rate. ABCA1-mediated cholesterol efflux on day 41 was markedly increased, whereas scavenger receptor type B1 (SRB1) and ABCG1-mediated effluxes were only weakly increased. Strong increase of FC is due to sustained stimulation of ABCA1-mediated efflux, and drop in HDL and formation of large apoE-rich particles are due to lack of LCAT activation.
Collapse
|
268
|
|
269
|
Bi X, Zhu X, Duong M, Boudyguina EY, Wilson MD, Gebre AK, Parks JS. Liver ABCA1 deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis. Arterioscler Thromb Vasc Biol 2013; 33:2288-96. [PMID: 23814116 DOI: 10.1161/atvbaha.112.301110] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Hepatic ATP binding cassette transporter A1 (ABCA1) expression is critical for maintaining plasma high-density lipoprotein (HDL) concentrations, but its role in macrophage reverse cholesterol transport and atherosclerosis is not fully understood. We investigated atherosclerosis development and reverse cholesterol transport in hepatocyte-specific ABCA1 knockout (HSKO) mice in the low-density lipoprotein (LDL) receptor KO (LDLrKO) C57BL/6 background. APPROACH AND RESULTS Male and female LDLrKO and HSKO/LDLrKO mice were switched from chow at 8 weeks of age to an atherogenic diet (10% palm oil, 0.2% cholesterol) for 16 weeks. Chow-fed HSKO/LDLrKO mice had HDL concentrations 10% to 20% of LDLrKO mice, but similar very low-density lipoprotein and LDL concentrations. Surprisingly, HSKO/LDLrKO mice fed the atherogenic diet had significantly lower (40% to 60%) very low-density lipoprotein, LDL, and HDL concentrations (50%) compared with LDLrKO mice. Aortic surface lesion area and cholesterol content were similar for both genotypes of mice, but aortic root intimal area was significantly lower (20% to 40%) in HSKO/LDLrKO mice. Although macrophage (3)H-cholesterol efflux to apoB lipoprotein-depleted plasma was 24% lower for atherogenic diet-fed HSKO/LDLrKO versus LDLrKO mice, variation in percentage efflux among individual mice was <2-fold compared with a 10-fold variation in plasma HDL concentrations, suggesting that HDL levels, per se, were not the primary determinant of plasma efflux capacity. In vivo reverse cholesterol transport, resident peritoneal macrophage sterol content, biliary lipid composition, and fecal cholesterol mass were similar between both genotypes of mice. CONCLUSIONS The markedly reduced plasma HDL pool in HSKO/LDLrKO mice is sufficient to maintain macrophage reverse cholesterol transport, which, along with reduced plasma very low-density lipoprotein and LDL concentrations, prevented the expected increase in atherosclerosis.
Collapse
Affiliation(s)
- Xin Bi
- From the Section on Lipid Sciences, Department of Pathology (X.B., X.Z., M.D., E.Y.B., M.D.W., A.K.G., J.S.P.), and Department of Biochemistry (J.S.P.), Wake Forest School of Medicine, Winston-Salem, NC
| | | | | | | | | | | | | |
Collapse
|
270
|
Hafiane A, Genest J. HDL, Atherosclerosis, and Emerging Therapies. CHOLESTEROL 2013; 2013:891403. [PMID: 23781332 PMCID: PMC3678415 DOI: 10.1155/2013/891403] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/27/2013] [Revised: 04/22/2013] [Accepted: 04/30/2013] [Indexed: 12/21/2022]
Abstract
This review aims to provide an overview on the properties of high-density lipoproteins (HDLs) and their cardioprotective effects. Emergent HDL therapies will be presented in the context of the current understanding of HDL function, metabolism, and protective antiatherosclerotic properties. The epidemiological association between levels of HDL-C or its major apolipoprotein (apoA-I) is strong, graded, and coherent across populations. HDL particles mediate cellular cholesterol efflux, have antioxidant properties, and modulate vascular inflammation and vasomotor function and thrombosis. A link of causality has been cast into doubt with Mendelian randomization data suggesting that genes causing HDL-C deficiency are not associated with increased cardiovascular risk, nor are genes associated with increased HDL-C, with a protective effect. Despite encouraging data from small studies, drugs that increase HDL-C levels have not shown an effect on major cardiovascular end-points in large-scale clinical trials. It is likely that the cholesterol mass within HDL particles is a poor biomarker of therapeutic efficacy. In the present review, we will focus on novel therapeutic avenues and potential biomarkers of HDL function. A better understanding of HDL antiatherogenic functions including reverse cholesterol transport, vascular protective and antioxidation effects will allow novel insight on novel, emergent therapies for cardiovascular prevention.
Collapse
Affiliation(s)
| | - Jacques Genest
- Faculty of Medicine, Center for Innovative Medicine, McGill University Health Center, Royal Victoria Hospital, McGill University, 687 Pine Avenue West, Montreal, QC, Canada H3A 1A1
| |
Collapse
|
271
|
Uehara Y, Ando S, Yahiro E, Oniki K, Ayaori M, Abe S, Kawachi E, Zhang B, Shioi S, Tanigawa H, Imaizumi S, Miura SI, Saku K. FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in ApoE-deficient mice. J Am Heart Assoc 2013; 2:e000048. [PMID: 23709562 PMCID: PMC3698760 DOI: 10.1161/jaha.113.000048] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Background Apolipoprotein (apo) A‐I is a major high‐density lipoprotein (HDL) protein that causes cholesterol efflux from peripheral cells through the ATP‐binding cassette transporter A1 (ABCA1), thus generating HDL and reversing the macrophage foam cell phenotype. Pre‐β1 HDL is the smallest subfraction of HDL, which is believed to represent newly formed HDL, and it is the most active acceptor of free cholesterol. Furthermore it has a possible protective function against cardiovascular disease (CVD). We developed a novel apoA‐I mimetic peptide without phospholipids (Fukuoka University ApoA‐I Mimetic Peptide, FAMP). Methods and Results FAMP type 5 (FAMP5) had a high capacity for cholesterol efflux from A172 cells and mouse and human macrophages in vitro, and the efflux was mainly dependent on ABCA1 transporter. Incubation of FAMP5 with human HDL or whole plasma generated small HDL particles, and charged apoA‐I‐rich particles migrated as pre‐β HDL on agarose gel electrophoresis. Sixteen weeks of treatment with FAMP5 significantly suppressed aortic plaque formation (scrambled FAMP, 31.3±8.9% versus high‐dose FAMP5, 16.2±5.0%; P<0.01) and plasma C‐reactive protein and monocyte chemoattractant protein‐1 in apoE‐deficient mice fed a high‐fat diet. In addition, it significantly enhanced HDL‐mediated cholesterol efflux capacity from the mice. Conclusions A newly developed apoA‐I mimetic peptide, FAMP, has an antiatherosclerotic effect through the enhancement of the biological function of HDL. FAMP may have significant atheroprotective potential and prove to be a new therapeutic tool for CVD.
Collapse
|
272
|
Salminen A, Pussinen PJ, Payne JB, Stoner JA, Jauhiainen M, Golub LM, Lee HM, Thompson DM, Sorsa T. Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages. Inflamm Res 2013; 62:711-20. [PMID: 23649042 DOI: 10.1007/s00011-013-0626-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Revised: 03/07/2013] [Accepted: 04/16/2013] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVE Subantimicrobial-dose doxycycline (SDD) treatment has been reported to reduce the severity of chronic inflammation and to increase serum high-density lipoprotein cholesterol. In a double-blind, placebo-controlled clinical trial, we determined whether SDD affects the ability of serum to facilitate cholesterol removal from macrophages. METHODS Forty-five postmenopausal osteopenic women with periodontitis were randomly assigned to take placebo (n = 26) or doxycycline hyclate (20 mg, n = 19) tablets twice daily for 2 years. Serum samples were collected at baseline, 1-, and 2-year appointments. The cholesterol efflux capacity of serum from cultured human macrophages (THP-1) was measured. RESULTS SDD subjects demonstrated a significant increase in serum-mediated cholesterol efflux from macrophages at both time points compared to baseline (p < 0.04 for each). Mean cholesterol efflux levels over the first year of follow-up were 3.0 percentage points (unit change) higher among SDD subjects compared to placebo subjects (p = 0.010), while there was no significant difference in 2-year changes. There were no significant differences in the changes of apolipoprotein A-I, apolipoprotein A-II, or serum amyloid A levels between the groups. CONCLUSIONS Our results suggest that SDD treatment may reduce the risk of cardiovascular disease in this patient group by increasing the cholesterol efflux capacity of serum.
Collapse
Affiliation(s)
- Aino Salminen
- Institute of Dentistry, University of Helsinki, P.O. Box 63, 00014 Helsinki, Finland.
| | | | | | | | | | | | | | | | | |
Collapse
|
273
|
Abstract
The HDL hypothesis has suffered damage in the past few years. Clinical trials have shown that raising HDL cholesterol levels does not improve cardiovascular disease (CVD) outcomes. In addition, Mendelian randomization studies have shown that DNA variants that alter HDL cholesterol levels in populations are unrelated to incident CVD events. Balancing this deluge of negative data are substantial basic science data supporting the concept that raising HDL cholesterol levels reduces CVD risk. Also, functionally relevant HDL subfractions might be more important determinants of risk than overall HDL cholesterol levels. But, while wobbly, the HDL hypothesis is still standing, seemingly too big to fail owing to past intellectual, economic and psychological investments in the idea.
Collapse
Affiliation(s)
- Dominic S Ng
- Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael's Hospital, Shuter Wing, Room 3-041, 30 Bond Street, Toronto, ON M5B 1W8, Canada
| | | | | |
Collapse
|
274
|
Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, Zimetti F, Adorni MP, Bernini F, Meroni PL. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2013; 73:609-15. [PMID: 23562986 DOI: 10.1136/annrheumdis-2012-202914] [Citation(s) in RCA: 129] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES The marked cardiovascular risk in autoimmune diseases is only partly explained. The capacity of high-density lipoproteins (HDL) to promote cell cholesterol efflux is a property with a well-known anti-atherogenic significance, but is also involved in functional modulation of endothelial and immune cells. The aim of this work was to evaluate HDL functionality with respect to cell cholesterol efflux in rheumatoid arthritis (RA) and systemic lupus erythemathosus (SLE) patients. METHODS We evaluated serum cholesterol efflux capacity (CEC) of apoB-depleted serum, which mainly reflects HDL activity, from 30 RA and 30 SLE patients, and from 30 healthy controls by radioisotopic ex-vivo systems discriminating between the specific pathways of cholesterol efflux. RESULTS RA patients presented impairment of ATP-binding cassette G1-mediated CEC that correlated with disease activity. SLE patients showed a more complex pattern of modifications unrelated to disease activity, with marked reduction of ATP-binding cassette G1-mediated CEC and impairment of ATP-binding cassette A1-mediated CEC. The relationship between specific pathways of CEC values and serum total HDL differed between groups and there was no relationship with autoantibody profile or current therapy. CONCLUSIONS CEC is impaired in RA and SLE, with a specific mechanism pattern in each disease not depending on serum HDL levels. These findings provide a new mechanism for the increased atherosclerotic risk in RA and SLE patients.
Collapse
|
275
|
Lyssenko NN, Nickel M, Tang C, Phillips MC. Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability. FASEB J 2013; 27:2880-92. [PMID: 23543682 PMCID: PMC3688743 DOI: 10.1096/fj.12-216564] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Nascent high-density lipoprotein (HDL) particles arise in different sizes. We have sought to uncover factors that control this size heterogeneity. Gel filtration, native PAGE, and protein cross-linking were used to analyze the size heterogeneity of nascent HDL produced by BHK-ABCA1, RAW 264.7, J774, and HepG2 cells under different levels of two factors considered as a ratio, the availability of apolipoprotein AI (apoAI) -accessible cell lipid, and concentration of extracellular lipid-free apoAI. Increases in the available cell lipid:apoAI ratio due to either elevated ATP-binding cassette transporter A1 (ABCA1) expression and activity or raised cell density (i.e., increasing numerator) shifted the production of nascent HDL from smaller particles with fewer apoAI molecules per particle and fewer molecules of choline-phospholipid and cholesterol per apoAI molecule to larger particles that contained more apoAI and more lipid per molecule of apoAI. A further shift to larger particles was observed in BHK-ABCA1 cells when the available cell lipid:apoAI ratio was raised still higher by decreasing the apoAI concentration (i.e., the denominator). These changes in nascent HDL biogenesis were reminiscent of the transition that occurs in the size composition of reconstituted HDL in response to an increasing initial lipid:apoAI molar ratio. Thus, the ratio of available cell lipid:apoAI is a fundamental cause of nascent HDL size heterogeneity, and rHDL formation is a good model of nascent HDL biogenesis.—Lyssenko, N. N., Nickel, M., Tang, C., Phillips, M. C. Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability.
Collapse
Affiliation(s)
- Nicholas N Lyssenko
- Lipid Research Group, Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | | | | | | |
Collapse
|
276
|
Li XM, Tang WHW, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013; 33:1696-705. [PMID: 23520163 DOI: 10.1161/atvbaha.113.301373] [Citation(s) in RCA: 256] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Diminished cholesterol efflux activity of apolipoprotein B (apoB)-depleted serum is associated with prevalent coronary artery disease, but its prognostic value for incident cardiovascular events is unclear. We investigated the relationship of cholesterol efflux activity with both prevalent coronary artery disease and incident development of major adverse cardiovascular events (death, myocardial infarction, or stroke). APPROACH AND RESULTS Cholesterol efflux activity from free cholesterol-enriched macrophages was measured in 2 case-control cohorts: (1) an angiographic cohort (n=1150) comprising stable subjects undergoing elective diagnostic coronary angiography and (2) an outpatient cohort (n=577). Analysis of media from cholesterol efflux assays revealed that the high-density lipoprotein fraction (1.063<d<1.21) contained only a minority (≈ 40%) of [(14)C]cholesterol released, with the majority found within the lipoprotein particle-depleted fraction, where ≈ 60% was recovered after apolipoprotein A1 immunoprecipitation. Albumin immunoprecipitation recovered another ≈ 30% of radiolabeled cholesterol within this fraction. Enhanced cholesterol efflux activity from ATP-binding cassette transporter A1-stimulated macrophages was associated with reduced risk of prevalent coronary artery disease in unadjusted models within both cohorts; however, the inverse risk relationship remained significant after adjustment for traditional coronary artery disease risk factors only within the outpatient cohort. Surprisingly, higher cholesterol efflux activity was associated with increase in prospective (3 years) risk of myocardial infarction/stroke (adjusted hazard ratio, 2.19; 95% confidence interval, 1.02-4.74) and major adverse cardiovascular events (adjusted hazard ratio, 1.85; 95% confidence interval, 1.11-3.06). CONCLUSIONS Heightened cholesterol efflux to apoB-depleted serum was paradoxically associated with increased prospective risk for myocardial infarction, stroke, and death. The majority of released radiolabeled cholesterol from macrophages in cholesterol efflux activity assays does not reside within a high-density lipoprotein particle.
Collapse
Affiliation(s)
- Xin-Min Li
- Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
277
|
Nguyen D, Nickel M, Mizuguchi C, Saito H, Lund-Katz S, Phillips MC. Interactions of apolipoprotein A-I with high-density lipoprotein particles. Biochemistry 2013; 52:1963-72. [PMID: 23425306 PMCID: PMC3603221 DOI: 10.1021/bi400032y] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Although the partitioning of apolipoprotein A-I (apoA-I) molecules in plasma between high-density lipoprotein (HDL)-bound and -unbound states is an integral part of HDL metabolism, the factors that control binding of apoA-I to HDL particles are poorly understood. To address this gap in knowledge, we investigated how the properties of the apoA-I tertiary structure domains and surface characteristics of spherical HDL particles influence apoA-I binding. The abilities of (14)C-labeled human and mouse apoA-I variants to associate with human HDL and lipid emulsion particles were determined using ultracentrifugation to separate free and bound protein. The binding of human apoA-I (243 amino acids) to HDL is largely mediated by its relatively hydrophobic C-terminal domain; the isolated N-terminal helix bundle domain (residues 1-190) binds poorly. Mouse apoA-I, which has a relatively polar C-terminal domain, binds to human HDL to approximately half the level of human apoA-I. The HDL binding abilities of apoA-I variants correlate strongly with their abilities to associate with phospholipid (PL)-stabilized emulsion particles, consistent with apoA-I-PL interactions at the particle surface being important. When equal amounts of HDL2 and HDL3 are present, all of the apoA-I variants partition preferentially to HDL3. Fluorescence polarization measurements using Laurdan-labeled HDL2 and HDL3 indicate that PL molecular packing is looser on the more negatively charged HDL3 particle surface, which promotes apoA-I binding. Overall, it is clear that both apoA-I structural features, especially the hydrophobicity of the C-terminal domain, and HDL surface characteristics such as the availability of free space influence the ability of apoA-I to associate with HDL particles.
Collapse
Affiliation(s)
- David Nguyen
- Lipid Research Group, Gastroenterology, Hepatology and Nutrition Division, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104-4318, United States
| | | | | | | | | | | |
Collapse
|
278
|
Martín-Peláez S, Covas MI, Fitó M, Kušar A, Pravst I. Health effects of olive oil polyphenols: recent advances and possibilities for the use of health claims. Mol Nutr Food Res 2013; 57:760-71. [PMID: 23450515 DOI: 10.1002/mnfr.201200421] [Citation(s) in RCA: 164] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2012] [Revised: 12/19/2012] [Accepted: 12/19/2012] [Indexed: 01/20/2023]
Abstract
The Mediterranean diet and consumption of olive oil have been connected in several studies with longevity and a reduced risk of morbidity and mortality. Lifestyle, such as regular physical activity, a healthy diet, and the existing social cohesion in Southern European countries have been recognised as candidate protective factors that may explain the Mediterranean Paradox. Along with some other characteristics of the Mediterranean diet, the use of olive oil as the main source of fat is common in Southern European countries. The benefits of consuming olive oil have been known since antiquity and were traditionally attributed to its high content in oleic acid. However, it is now well established that these effects must also be attributed to the phenolic fraction of olive oil with its anti-oxidant, anti-inflammatory and anti-microbial activities. The mechanisms of these activities are varied and probably interconnected. For some activities of olive oil phenolic compounds, the evidence is already strong enough to enable the legal use of health claims on foods. This review discusses the health effects of olive oil phenols along with the possibilities of communicating these effects on food labels.
Collapse
Affiliation(s)
- Sandra Martín-Peláez
- Cardiovascular Risk and Nutrition Research Group (CARIN), Research in Inflammatory and Cardiovascular Disorders (RICAD), Barcelona, Spain
| | | | | | | | | |
Collapse
|
279
|
Bonamassa B, Moschetta A. Atherosclerosis: lessons from LXR and the intestine. Trends Endocrinol Metab 2013; 24:120-8. [PMID: 23158108 DOI: 10.1016/j.tem.2012.10.004] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2012] [Revised: 10/12/2012] [Accepted: 10/18/2012] [Indexed: 12/17/2022]
Abstract
Modulation of the cholesterol-sensing liver X receptors (LXRs) and their downstream targets has emerged as promising therapeutic avenues in atherosclerosis. The intestine is important for its unique capabilities to act as a gatekeeper for cholesterol absorption and to participate in the process of cholesterol elimination in the feces and reverse cholesterol transport (RCT). Pharmacological and genetic intestine-specific LXR activation have been shown to protect against atherosclerosis. In this review we discuss the LXR-targeted molecular players in the enterocytes as well as the intestine-driven pathways contributing to cholesterol homeostasis with therapeutic potential as targets in the prevention and treatment of atherosclerosis..
Collapse
Affiliation(s)
- Barbara Bonamassa
- Laboratory of Lipid Metabolism and Cancer, Department of Translational Pharmacology, Consorzio Mario Negri Sud, Via Nazionale 8/A, 66030 Santa Maria Imbaro (CH), Italy
| | | |
Collapse
|
280
|
Vivekanandan-Giri A, Slocum JL, Byun J, Tang C, Sands RL, Gillespie BW, Heinecke JW, Saran R, Kaplan MJ, Pennathur S. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis 2013; 72:1725-31. [PMID: 23313808 DOI: 10.1136/annrheumdis-2012-202033] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
OBJECTIVE Phagocyte-derived myeloperoxidase (MPO) and pro-inflammatory high density lipoprotein (HDL) associate with rheumatoid arthritis (RA), but the link between MPO and HDL has not been systematically examined. In this study, we investigated whether MPO can oxidise HDL and determined MPO-specific oxidative signature by apoA-1 by peptide mapping in RA subjects with and without known cardiovascular disease (CVD). METHODS Two MPO oxidation products, 3-chlorotyrosine and 3-nitrotyrosine, were quantified by tandem mass spectrometry (MS/MS) in in vitro model system studies and in plasma and HDL derived from healthy controls and RA subjects. MPO levels and cholesterol efflux were determined. Site-specific nitration and chlorination of apoA-1 peptides were quantified by MS/MS. RESULTS RA subjects demonstrated higher levels of MPO, MPO-oxidised HDL and diminished cholesterol efflux. There was marked increase in MPO-specific 3-chlorotyrosine and 3-nitrotyrosine content in HDL in RA subjects consistent with specific targeting of HDL, with increased nitration in RA subjects with CVD. Cholesterol efflux capacity was diminished in RA subjects and correlated inversely with HDL 3-chlorotyrosine suggesting a mechanistic role for MPO. Nitrated HDL was elevated in RACVD subjects compared with RA subjects without CVD. Oxidative peptide mapping revealed site-specific unique oxidation signatures on apoA-1 for RA subjects with and without CVD. CONCLUSIONS We report an increase in MPO-mediated HDL oxidation that is regiospecific in RA and accentuated in those with CVD. Decreased cholesterol efflux capacity due to MPO-mediated chlorination is a potential mechanism for atherosclerosis in RA and raises the possibility that oxidant resistant forms of HDL may attenuate this increased risk.
Collapse
|
281
|
Murakami H, Tanabe J, Tamasawa N, Matsumura K, Yamashita M, Matsuki K, Murakami H, Matsui J, Suda T. Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes. Diabetes Res Clin Pract 2013; 99:30-8. [PMID: 23137417 DOI: 10.1016/j.diabres.2012.10.022] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Revised: 10/18/2012] [Accepted: 10/22/2012] [Indexed: 12/17/2022]
Abstract
AIMS Cholesterol efflux with high-density lipoprotein (HDL) particles has an important role in the first step of reverse cholesterol transport (RCT). However, HDL function in type 2 diabetes has not been well investigated thoroughly. We measured cholesterol efflux in 36 patients with type 2 diabetes compared with 9 controls without diabetes. METHODS The HDL fraction was separated with polyacrylamide gel and recovered using the protein recovery system. Concentration adjusted HDL fraction was used to determine HDL-mediated cholesterol efflux (Efflux-hdl) from THP-1 derived macrophages. We measured paraoxonase-1 (PON 1) activity to determine antioxidation capacity, serum amyloid A protein (SAA) to determine inflammatory response, and carboxymethyl-lysin (CML) to determine antiglucoxidative capacity. RESULTS Efflux-hdl demonstrated no correlation with plasma apoprotein A-1 (ApoA-I) or HDL-cholesterol in patients with diabetes. PON1 activity in the patients' HDL fraction was positively correlated with Efflux-hdl (r=0.39, p=0.02), and showed a negative tendency with HbA1c levels (r=-0.28, p=0.10). SAA and CML levels did not demonstrate correlation with Efflux-hdl in patients with diabetes. CONCLUSION We confirmed the functional changes in HDL particles in the patients. Efflux-hdl from macrophages was reduced depending upon the decrease in PON1 activity, which was inversely related to HbA1c levels.
Collapse
Affiliation(s)
- Hiroshi Murakami
- Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Zaifu-5, Hirosaki Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
282
|
Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, Horiguchi M, Nakamura T, Chonabayashi K, Hishizawa M, Hasegawa K, Kume N, Yokode M, Kita T, Kimura T, Ono K. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc 2012; 1:e003376. [PMID: 23316322 PMCID: PMC3540673 DOI: 10.1161/jaha.112.003376] [Citation(s) in RCA: 173] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2012] [Accepted: 09/28/2012] [Indexed: 01/03/2023]
Abstract
Background Cholesterol efflux from cells to apolipoprotein A-I (apoA-I) acceptors via the ATP-binding cassette transporters ABCA1 and ABCG1 is thought to be central in the antiatherogenic mechanism. MicroRNA (miR)-33 is known to target ABCA1 and ABCG1 in vivo. Methods and Results We assessed the impact of the genetic loss of miR-33 in a mouse model of atherosclerosis. MiR-33 and apoE double-knockout mice (miR-33−/−Apoe−/−) showed an increase in circulating HDL-C levels with enhanced cholesterol efflux capacity compared with miR-33+/+Apoe−/− mice. Peritoneal macrophages from miR-33−/−Apoe−/− mice showed enhanced cholesterol efflux to apoA-I and HDL-C compared with miR-33+/+Apoe−/− macrophages. Consistent with these results, miR-33−/−Apoe−/− mice showed reductions in plaque size and lipid content. To elucidate the roles of miR-33 in blood cells, bone marrow transplantation was performed in these mice. Mice transplanted with miR-33−/−Apoe−/− bone marrow showed a significant reduction in lipid content in atherosclerotic plaque compared with mice transplanted with miR-33+/+Apoe−/− bone marrow, without an elevation of HDL-C. Some of the validated targets of miR-33 such as RIP140 (NRIP1) and CROT were upregulated in miR-33−/−Apoe−/− mice compared with miR-33+/+Apoe−/− mice, whereas CPT1a and AMPKα were not. Conclusions These data demonstrate that miR-33 deficiency serves to raise HDL-C, increase cholesterol efflux from macrophages via ABCA1 and ABCG1, and prevent the progression of atherosclerosis. Many genes are altered in miR-33-deficient mice, and detailed experiments are required to establish miR-33 targeting therapy in humans.
Collapse
Affiliation(s)
- Takahiro Horie
- Department of Cardiovascular Medicine, Kyoto University, Kyoto, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
283
|
De Meyer I, Martinet W, De Meyer GRY. Therapeutic strategies to deplete macrophages in atherosclerotic plaques. Br J Clin Pharmacol 2012; 74:246-63. [PMID: 22309283 DOI: 10.1111/j.1365-2125.2012.04211.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Macrophages can be found in all stages of atherosclerosis and are major contributors of atherosclerotic plaque development, progression and destabilization. Continuous recruitment of monocytes drives this chronic inflammatory disease, which can be intervened by several strategies: reducing the inflammatory stimulus by lowering circulating lipids and promoting cholesterol efflux from plaque, direct and indirect targeting of adhesion molecules and chemokines involved in monocyte adhesion and transmigration and inducing macrophage death in atherosclerotic plaques in combination with anti-inflammatory drugs. This review discusses the outlined strategies to deplete macrophages from atherosclerotic plaques to promote plaque stabilization.
Collapse
Affiliation(s)
- Inge De Meyer
- Division of Physiopharmacology, University of Antwerp, Antwerp, Belgium.
| | | | | |
Collapse
|
284
|
Favari E, Ronda N, Adorni MP, Zimetti F, Salvi P, Manfredini M, Bernini F, Borghi C, Cicero AFG. ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects. J Lipid Res 2012; 54:238-43. [PMID: 23103472 DOI: 10.1194/jlr.p030452] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The capacity of HDL to induce cell cholesterol efflux is considered one of its main antiatherogenic properties. Little is known about the impact of such HDL function on vascular physiology. We investigated the relationship between ABCA1-dependent serum cholesterol efflux capacity (CEC), an HDL functionality indicator, and pulse wave velocity (PWV), an indicator of arterial stiffness. Serum of 167 healthy subjects was used to conduct CEC measurement, and carotid-femoral PWV was measured with a high-fidelity tonometer. J774 macrophages, labeled with [(3)H]cholesterol and stimulated to express ABCA1, were exposed to sera; the difference between cholesterol efflux from stimulated and unstimulated cells provided specific ABCA1-mediated CEC. PWV is inversely correlated with ABCA1-dependent CEC (r = -0.183; P = 0.018). Moreover, controlling for age, sex, body mass index, mean arterial pressure, serum LDL, HDL-cholesterol, and fasting plasma glucose, PWV displays a significant negative regression on ABCA1-dependent CEC (β = -0.204; 95% confidence interval, -0.371 to -0.037). The finding that ABCA1-dependent CEC, but not serum HDL cholesterol level (r = -0.002; P = 0.985), is a significant predictor of PWV in healthy subjects points to the relevance of HDL function in vascular physiology and arterial stiffness prevention.
Collapse
Affiliation(s)
- Elda Favari
- Department of Pharmacological and Biological Sciences and Applied Chemistries, University of Parma, Parma, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
285
|
Vaisar T. Proteomics investigations of HDL: challenges and promise. Curr Vasc Pharmacol 2012; 10:410-21. [PMID: 22339300 DOI: 10.2174/157016112800812755] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2011] [Revised: 09/01/2011] [Accepted: 11/06/2011] [Indexed: 02/02/2023]
Abstract
High density lipoprotein (HDL) is recognized as the major negative risk factor of cardiovascular disease and number of anti-atherogenic functions has been ascribed to HDL. HDL is an assembly of a neutral lipid core and an outer shell consisting of polar lipids and proteins. It has been defined many different ways based on various distinct properties including density flotation, protein composition, molecular size, and electrophoretic migration. Overall the studies characterizing HDL clearly demonstrate that it is a complex heterogeneous mixture of particles. Furthermore several studies convincingly demonstrated that certain populations of HDL particles have a distinct functionality suggesting that HDL may serve as a platform for assembly of protein complexes with very specific biological functions. Indeed recent proteomics studies described over 100 proteins associated with HDL. Here we review approaches to isolation and proteomic analysis of HDL and discuss potential problems associated with isolation methods which may confound our understanding of the relation of the HDL composition and its biological function.
Collapse
Affiliation(s)
- Tomáš Vaisar
- Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, 815 Mercer St, Seattle, WA 98109, USA.
| |
Collapse
|
286
|
Aicher BO, Haser EK, Freeman LA, Carnie AV, Stonik JA, Wang X, Remaley AT, Kato GJ, Cannon III RO. Diet-induced weight loss in overweight or obese women and changes in high-density lipoprotein levels and function. Obesity (Silver Spring) 2012; 20:2057-62. [PMID: 22402736 PMCID: PMC3374067 DOI: 10.1038/oby.2012.56] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Diet-induced weight loss in women may be associated with decreases not only in plasma levels of low-density lipoprotein cholesterol (LDL-C), but also in high-density lipoprotein cholesterol (HDL-C). Whether a decrease in HDL-C is associated with altered HDL function is unknown. One hundred overweight or obese women (age 46 ± 11 years, 60 black; 12 diabetic) were enrolled in the 6-month program of reduced fat and total energy diet and low-intensity exercise. Serum cholesterol efflux capacity was measured in (3)H-cholesterol-labeled BHK cells expressing ABCA1, ABCG1, or SR-B1 transporters and incubated with 1% apolipoprotein B (apoB)-depleted serum. Antioxidant properties of HDL were estimated by paraoxonase-1 (PON1) activity and oxygen radical absorbance capacity (ORAC). Endothelial nitric oxide synthase (eNOS) activation was measured by conversion of L-arginine to L-citrulline in endothelial cells incubated with HDL from 49 subjects. Participants achieved an average weight loss of 2.2 ± 3.9 kg (P < 0.001), associated with reductions in both LDL-C (-6 ± 21 mg/dl, P = 0.004) and HDL-C (-3 ± 9 mg/dl, P = 0.016). Cholesterol efflux capacity by the ABCA1 transporter decreased by 10% (P = 0.006); efflux capacities by the ABCG1 and SR-B1 transporters were not significantly altered. ORAC decreased by 15% (P = 0.018); neither PON1 activity nor eNOS activation was significantly altered by reduction in HDL-C. Findings were similar for diabetic and nondiabetic subjects. Diet-induced weight loss in overweight or obese women is associated with a decrease in HDL-C levels, but overall HDL function is relatively spared, suggesting that decrease in HDL-C in this setting is not deleterious to cardiovascular risk.
Collapse
Affiliation(s)
- Brittany O. Aicher
- Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
| | - Erin K. Haser
- Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
| | - Lita A. Freeman
- Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
| | - Andrea V. Carnie
- Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
| | - John A. Stonik
- Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
| | - Xunde Wang
- Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
| | - Alan T. Remaley
- Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
| | - Gregory J. Kato
- Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
| | - Richard O. Cannon III
- Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
- ()
| |
Collapse
|
287
|
Villard EF, El Khoury P, Duchene E, Bonnefont-Rousselot D, Clement K, Bruckert E, Bittar R, Le Goff W, Guerin M. Elevated CETP Activity Improves Plasma Cholesterol Efflux Capacity From Human Macrophages in Women. Arterioscler Thromb Vasc Biol 2012; 32:2341-9. [DOI: 10.1161/atvbaha.112.252841] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
We aim to identify the impact of endogenous cholesteryl ester transfer protein (CETP) activity on plasma capacity to mediate free cholesterol efflux from human macrophages.
Methods and Results—
Endogenous plasma CETP activity was measured in a population of 348 women. We defined a low CETP group corresponding to subjects displaying an endogenous plasma CETP activity within the first tertile and a high CETP group corresponding to subjects with an endogenous plasma CETP activity within the third tertile. Subjects from the high CETP activity group displayed a significant increase in the capacity of their plasma (+8.2%;
P
=0.001) to mediate cholesterol efflux from human acute monocytic leukemia cell line human macrophages and from ATP-binding cassette transporter A1-dependent pathway (+23.4%;
P
=0.0001) as compared with those from the low CETP activity group. Multivariate analyses revealed that the impact of CETP activity was independent of plasma lipids levels. Pre–β1-high-density lipoprotein concentrations were significantly elevated (+29.6%;
P
=0.01) in the high CETP activity group as compared with the low CETP activity group. A positive correlation between pre–β1-high-density lipoprotein levels and plasma efflux efficiency from human acute monocytic leukemia cell line human macrophages was observed (
r
=0.29,
P
=0.02).
Conclusion—
CETP leading to the improvement of plasma efflux capacity, as a result of efficient pre–β-high-density lipoprotein formation and ATP-binding cassette transporter A1 efflux, should be preserved to prevent lipid accumulation in human macrophages.
Collapse
Affiliation(s)
- Elise F. Villard
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Petra El Khoury
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Emilie Duchene
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Dominique Bonnefont-Rousselot
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Karine Clement
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Eric Bruckert
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Randa Bittar
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Wilfried Le Goff
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Maryse Guerin
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| |
Collapse
|
288
|
|
289
|
Peters SAE, Lind L, Palmer MK, Grobbee DE, Crouse JR, O'Leary DH, Evans GW, Raichlen J, Bots ML, den Ruijter HM. Increased age, high body mass index and low HDL-C levels are related to an echolucent carotid intima-media: the METEOR study. J Intern Med 2012; 272:257-66. [PMID: 22172243 DOI: 10.1111/j.1365-2796.2011.02505.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Echolucent plaques are related to a higher cardiovascular risk. Studies to investigate the relationship between echolucency and cardiovascular risk in the early stages of atherosclerosis are limited. We studied the relationship between cardiovascular risk factors and echolucency of the carotid intima-media in low-risk individuals. METHODS Data were analysed from the Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin (METEOR) study, a randomized placebo-controlled trial including 984 individuals which showed that rosuvastatin attenuated the rate of change of carotid intima-media thickness (CIMT). In this post hoc analysis, duplicate baseline ultrasound images from the far wall of the left and right common carotid arteries were used for the evaluation of the echolucency of the carotid intima-media, measured by grey-scale median (GSM) on a scale of 0-256. Low GSM values reflect echolucent, whereas high values reflect echogenic structures. The relationship between baseline GSM and cardiovascular risk factors was evaluated using linear regression models. RESULTS Mean baseline GSM (± SD) was 84 ± 29. Lower GSM of the carotid intima-media was associated with older age, high body mass index (BMI) and low levels of high-density lipoprotein cholesterol (HDL-C) [beta -4.49, 95% confidence interval (CI) -6.50 to -2.49; beta -4.51, 95% CI -6.43 to -2.60; beta 2.45, 95% CI 0.47 to 4.42, respectively]. Common CIMT was inversely related to GSM of the carotid intima-media (beta -3.94, 95% CI -1.98 to -5.89). CONCLUSION Older age, high BMI and low levels of HDL-C are related to echolucency of the carotid intima-media. Hence, echolucency of the carotid intima-media may be used as a marker of cardiovascular risk profile to provide more information than thickness alone.
Collapse
Affiliation(s)
- S A E Peters
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
290
|
Abstract
PURPOSE OF REVIEW A negative correlation between HDL cholesterol levels and risk of coronary artery disease has long been recognized. Emerging knowledge of the molecular speciation and functional properties of HDL provides an opportunity to study the atheroprotective effects of specific metabolic processes. The discovery of the quantum particle among the molecular species of HDL (prebeta-1 HDL) and its role in cholesterol efflux from the artery wall, offer a means of assessing the efficiency of efflux. This review presents observations on the structure and metabolism of this particle and its emerging role as a predictor of risk for atherosclerotic vascular disease. RECENT FINDINGS Prebeta-1 HDL is now recognized as the primary acceptor of cholesterol effluxed by the dominant ATP-binding cassette A1 (ABCA1) transporter in arterial macrophages, a critical step in reverse cholesterol transport. Several studies have revealed an association between high levels of this particle and risk of globally defined coronary artery disease and carotid intima-media thickness. Recently, these findings have been confirmed and extended to include myocardial infarction. High levels of prebeta-1 HDL may serve as an index of functional impairment of cholesterol efflux or esterification, either of which would be expected to impede reverse cholesterol transport. SUMMARY Recent studies underscore the critical role of prebeta-1 HDL in reverse cholesterol transport and its use as a marker of risk for structural coronary disease, myocardial infarction, and cerebral vascular disease.
Collapse
Affiliation(s)
- John P Kane
- Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, California 94158, USA
| | | |
Collapse
|
291
|
Rubinow KB, Page ST. Testosterone, HDL and cardiovascular risk in men: the jury is still out. ACTA ACUST UNITED AC 2012; 7:363-365. [PMID: 25379057 DOI: 10.2217/clp.12.38] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
"Even when reductions in HDL-cholesterol are observed as a consequence of androgen therapy, the implications for cardiovascular risk modification remain highly uncertain."
Collapse
Affiliation(s)
- Katya B Rubinow
- Center for Research in Reproduction & Contraception, University of Washington School of Medicine, Seattle, WA, USA and Diabetes & Obesity Center of Excellence, Division of Metabolism, Endocrinology & Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
| | - Stephanie T Page
- Center for Research in Reproduction & Contraception, University of Washington School of Medicine, Seattle, WA, USA
| |
Collapse
|
292
|
Liver X receptor activation attenuates plaque formation and improves vasomotor function of the aortic artery in atherosclerotic ApoE−/− mice. Inflamm Res 2012; 61:1299-307. [DOI: 10.1007/s00011-012-0529-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2012] [Revised: 05/11/2012] [Accepted: 07/03/2012] [Indexed: 10/28/2022] Open
|
293
|
Page ST, Krauss RM, Gross C, Ishida B, Heinecke JW, Tang C, Amory JK, Schaefer PM, Cox CJ, Kane J, Purnell JQ, Weinstein RL, Vaisar T. Impact of mifepristone, a glucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function. J Clin Endocrinol Metab 2012; 97:1598-605. [PMID: 22399518 PMCID: PMC3339893 DOI: 10.1210/jc.2011-2813] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
CONTEXT Mifepristone is a glucocorticoid and progestin antagonist under investigation for the treatment of Cushing's syndrome. Mifepristone decreases high-density lipoprotein (HDL) cholesterol (HDL-C) levels in treated patients, but the clinical significance of this is unclear because recent studies suggest that functional properties of HDL predict cardiovascular disease status better than does HDL-C concentration. OBJECTIVE The aim of the study was to characterize the impact of mifepristone administration on HDL particle concentration and function. DESIGN AND SETTING We conducted a double-blind, randomized, placebo-controlled trial at a single-site, clinical research center. PARTICIPANTS Thirty healthy postmenopausal female volunteers participated in the study. INTERVENTION Individuals were randomized to receive daily oral mifepristone (600 mg) or placebo for 6 wk. MAIN OUTCOME MEASURES We measured HDL-C, serum HDL particle concentration, and HDL-mediated cholesterol efflux by treatment group. RESULTS As expected, ACTH, cortisol, estradiol, and testosterone levels increased in the mifepristone group. Mifepristone treatment decreased HDL-C and HDL particle concentration by 26 and 25%, respectively, but did not alter pre-β HDL concentration. In contrast, the serum HDL-mediated cholesterol efflux decreased with mifepristone treatment by only 12%, resulting in an effective increase of the efflux capacity per HDL particle. No changes were observed in cholesterol ester transfer protein or lecithin:cholesterol acyltransferase activity. CONCLUSIONS Treatment with mifepristone reduced HDL-C, HDL particle concentration, and serum HDL cholesterol efflux in postmenopausal women. However, on a per particle basis, the efflux capacity of serum HDL increased. These observations support the concept that a decrease in HDL-C may not represent proportional impairment of HDL function.
Collapse
Affiliation(s)
- Stephanie T Page
- Department of Medicine, University of Washington, Seattle, Washington 98195, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
294
|
In Vivo Inflammation Does Not Impair ABCA1-Mediated Cholesterol Efflux Capacity of HDL. CHOLESTEROL 2012; 2012:610741. [PMID: 22611487 PMCID: PMC3348631 DOI: 10.1155/2012/610741] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/26/2011] [Revised: 01/13/2012] [Accepted: 01/27/2012] [Indexed: 11/23/2022]
Abstract
HDL provides atheroprotection by facilitating cholesterol efflex from lipid-laden macrophages in the vessel wall. In vitro studies have suggested impaired efflux capacity of HDL following inflammatory changes. We assessed the impact of acute severe sepsis and mild chronic inflammatory disease on the efflux capacity of HDL. We hypothesize that a more severe inflammatory state leads to stronger impaired cholesterol efflux capacity. Using lipid-laden THP1 cells and fibroblasts we were able to show that efflux capacity of HDL from both patients with severe sepsis or with Crohn's disease (active or in remission), either isolated using density gradient ultracentrifugation or using apoB precipitation, was not impaired. Yet plasma levels of HDL cholesterol and apoA-I were markedly lower in patients with sepsis. Based on the current observations we conclude that inflammatory disease does not interfere with the capacity of HDL to mediate cholesterol efflux. Our findings do not lend support to the biological relevance of HDL function changes in vitro.
Collapse
|
295
|
Abstract
High-density lipoprotein (HDL) levels are inversely associated with coronary heart disease due to HDL's ability to transport excess cholesterol in arterial macrophages to the liver for excretion [i.e., reverse cholesterol transport (RCT)]. However, recent advances highlight additional atheroprotective roles for HDL beyond bulk cholesterol removal from cells through RCT. By promoting cellular free cholesterol (FC) efflux, HDL and its apolipoproteins (apoA-I and apoE) decrease plasma membrane FC and lipid raft content in immune and hematopoietic stem cells, decreasing inflammatory and cell proliferation signaling pathways. HDL and apoA-I also dampen inflammatory signaling pathways independent of cellular FC efflux. In addition, HDL lipid and protein cargo provide protection against parasitic and bacterial infection, endothelial damage, and oxidant toxicity. Here, current knowledge is reviewed regarding the role of HDL and its apolipoproteins in regulating cellular cholesterol homeostasis, highlighting recent advances on novel functions and mechanisms by which HDLs regulate inflammation and hematopoiesis.
Collapse
Affiliation(s)
- Xuewei Zhu
- Department of Pathology-Section on Lipid Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157, USA
| | | |
Collapse
|
296
|
Rosenson RS, Brewer HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012; 125:1905-19. [PMID: 22508840 PMCID: PMC4159082 DOI: 10.1161/circulationaha.111.066589] [Citation(s) in RCA: 706] [Impact Index Per Article: 58.8] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Robert S Rosenson
- Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
297
|
Rubinow KB, Tang C, Hoofnagle AN, Snyder CN, Amory JK, Heinecke JW, Page ST. Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men. Steroids 2012; 77:454-60. [PMID: 22266332 PMCID: PMC3304018 DOI: 10.1016/j.steroids.2012.01.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2011] [Revised: 12/29/2011] [Accepted: 01/03/2012] [Indexed: 10/14/2022]
Abstract
Exogenous androgens can lower HDL-cholesterol (HDL-C) concentrations, yet men with low serum testosterone have elevated rates of cardiovascular disease (CVD). HDL function may better predict CVD risk than absolute HDL-C quantity. We evaluated the acute effects of medical castration in men on HDL-C, cholesterol efflux capacity and HDL protein composition. Twenty-one healthy men, ages 18-55, received the GnRH antagonist acyline and one of the following for 28days: Group 1: placebo, Group 2: transdermal testosterone gel and placebo, Group 3: transdermal testosterone gel and an aromatase inhibitor. Sex steroids, fasting lipids, and cholesterol efflux to apoB-depleted serum were measured in all subjects. The HDL proteome was assessed in Group 1 subjects only. In Group 1, serum testosterone concentrations were reduced by >95%, and HDL-C and cholesterol efflux capacity increased (p=0.02 and p=0.03 vs. baseline, respectively). HDL-associated clusterin increased significantly with sex steroid withdrawal (p=0.007 vs. baseline). Testosterone withdrawal in young, healthy men increases HDL-C and cholesterol efflux capacity. Moreover, sex steroid deprivation changes HDL protein composition. Further investigation of the effects of sex steroids on HDL composition and function may help resolve the apparently conflicting data regarding testosterone, HDL-C, and CVD risk.
Collapse
Affiliation(s)
- Katya B Rubinow
- Center for Research in Reproduction and Contraception, Division of Metabolism, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98109, United States.
| | | | | | | | | | | | | |
Collapse
|
298
|
Adorni MP, Zimetti F, Puntoni M, Bigazzi F, Sbrana F, Minichilli F, Bernini F, Ronda N, Favari E, Sampietro T. Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis. J Lipid Res 2012; 53:984-989. [PMID: 22414482 DOI: 10.1194/jlr.p024810] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
High LDL-cholesterol (LDL-C) characterizes familial hypercholesterolemia (FH) and familial combined hyperlipidemia (FCH). LDL-apheresis, used in these patients to reduce LDL-C levels, has been shown to also affect HDL levels and composition. We studied LDL-apheresis effects on six FH and nine FCH subjects' serum capacity to modulate cellular cholesterol efflux, an index of HDL functionality, and to load macrophages with cholesterol. Serum cholesterol efflux capacity (CEC) and macrophage cholesterol loading capacity (CLC) were measured before, immediately after, and two days after LDL-apheresis. The procedure reduced total cholesterol (TC), LDL-C, and apoB plasma levels (-69%, -80% and -74%, respectively), parameters only partially restored two days later. HDL-C and apoA-I plasma levels, reduced after LDL-apheresis (-27% and -16%, respectively), were restored to almost normal levels two days later. LDL-apheresis reduced serum aqueous diffusion (AD) CEC, SR-BI-CEC, and ABCA1-CEC. AD and SR-BI were fully restored whereas ABCA1-CEC remained low two days later. Sera immediately and two days after LDL-apheresis had a lower CLC than pre-LDL-apheresis sera. In conclusion, LDL-apheresis transiently reduces HDL-C levels and serum CEC, but it also reduces also serum capacity to deliver cholesterol to macrophages. Despite a potentially negative effect on HDL levels and composition, LDL-apheresis may counteract foam cells formation.
Collapse
Affiliation(s)
- M P Adorni
- Department of Pharmacological and Biological Sciences and Applied Chemistries, University of Parma, Parma, Italy
| | - F Zimetti
- Department of Pharmacological and Biological Sciences and Applied Chemistries, University of Parma, Parma, Italy
| | - M Puntoni
- Department of Pharmacological and Biological Sciences and Applied Chemistries, CNR Institute of Clinical Physiology, Pisa, Italy
| | - F Bigazzi
- Department of Pharmacological and Biological Sciences and Applied Chemistries, Dyslipidemias and Atherosclerosis Laboratory, Fondazione Toscana Gabriele Monasterio, Pisa, Italy
| | - F Sbrana
- Department of Pharmacological and Biological Sciences and Applied Chemistries, Dyslipidemias and Atherosclerosis Laboratory, Fondazione Toscana Gabriele Monasterio, Pisa, Italy
| | - F Minichilli
- Department of Pharmacological and Biological Sciences and Applied Chemistries, CNR Institute of Clinical Physiology, Pisa, Italy
| | - F Bernini
- Department of Pharmacological and Biological Sciences and Applied Chemistries, University of Parma, Parma, Italy.
| | - N Ronda
- Department of Pharmacological and Biological Sciences and Applied Chemistries, University of Parma, Parma, Italy
| | - E Favari
- Department of Pharmacological and Biological Sciences and Applied Chemistries, University of Parma, Parma, Italy
| | - T Sampietro
- Department of Pharmacological and Biological Sciences and Applied Chemistries, CNR Institute of Clinical Physiology, Pisa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries, Dyslipidemias and Atherosclerosis Laboratory, Fondazione Toscana Gabriele Monasterio, Pisa, Italy
| |
Collapse
|
299
|
Pisciotta L, Favari E, Magnolo L, Simonelli S, Adorni MP, Sallo R, Fancello T, Zavaroni I, Ardigò D, Bernini F, Calabresi L, Franceschini G, Tarugi P, Calandra S, Bertolini S. Characterization of Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function Mutations of ANGPTL3. ACTA ACUST UNITED AC 2012; 5:42-50. [DOI: 10.1161/circgenetics.111.960674] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Angiopoietin-like protein 3 (ANGPTL3) affects lipid metabolism by inhibiting the activity of lipoprotein and endothelial lipases.
Angptl3
knockout mice have marked hypolipidemia, and heterozygous carriers of
ANGPLT3
, loss-of-function mutations were found among individuals in the lowest quartile of plasma triglycerides in population studies. Recently, 4 related individuals with primary hypolipidemia were found to be compound heterozygotes for
ANGPTL3
loss-of-function mutations.
Methods and Results—
We resequenced
ANGPTL3
in 4 members of 3 kindreds originally identified for very low levels of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (0.97±0.16 and 0.56±0.20 mmol/L, respectively) in whom no mutations of known candidate genes for monogenic hypobetalipoproteinemia and hypoalphalipoproteinemia had been detected. These subjects were found to be homozygous or compound heterozygous for
ANGPTL3
loss-of-function mutations (p.G400VfsX5, p.I19LfsX22/p.N147X) associated with the absence of ANGPTL3 in plasma. They had reduced plasma levels of triglyceride-containing lipoproteins and of HDL particles that contained only apolipoprotein A-I and pre-β–high-density lipoprotein. In addition, their apolipoprotein B–depleted sera had a reduced capacity to promote cell cholesterol efflux through the various pathways (ABCA1-, SR-BI–, and ABCG1-mediated efflux); however, these subjects had no clinical evidence of accelerated atherosclerosis. Heterozygous carriers of the
ANGPTL3
mutations had low plasma ANGPTL3 and moderately reduced low-density lipoprotein cholesterol (2.52±0.38 mmol/L) but normal plasma high-density lipoprotein cholesterol.
Conclusions—
Complete ANGPTL3 deficiency caused by loss-of-function mutations of
ANGPTL3
is associated with a recessive hypolipidemia characterized by a reduction of apolipoprotein B and apolipoprotein A-I–containing lipoproteins, changes in subclasses of high-density lipoprotein, and reduced cholesterol efflux potential of serum. Partial ANGPTL3 deficiency is associated only with a moderate reduction of low-density lipoprotein.
Collapse
Affiliation(s)
- Livia Pisciotta
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Elda Favari
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Lucia Magnolo
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Sara Simonelli
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Maria Pia Adorni
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Raffaella Sallo
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Tatiana Fancello
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Ivana Zavaroni
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Diego Ardigò
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Franco Bernini
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Laura Calabresi
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Guido Franceschini
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Patrizia Tarugi
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Sebastiano Calandra
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| | - Stefano Bertolini
- From the Department of Internal Medicine (L.P., R.S., S.B.), University of Genoa, Genoa, Italy; Department of Pharmacological and Biological Sciences and Applied Chemistries (E.F., M.P.A., F.B.) and Department of Internal Medicine and Biomedical Sciences (I.Z., D.A.), University of Parma, Parma, Italy; Department of Biomedical Sciences (L.M., T.F., P.T., S.C.), University of Modena and Reggio Emilia, Modena, Italy; and Center E. Grossi Paoletti (S.S., L.C., G.F.), Department of Pharmacological
| |
Collapse
|
300
|
Camont L, Chapman J, Kontush A. Functionality of HDL particles: Heterogeneity and relationships to cardiovascular disease. ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS 2011. [DOI: 10.1016/s1878-6480(11)70784-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|